Status:
ENROLLING_BY_INVITATION
The Efficacy of 10-day and 14-day Bismuth-based Quadruple Therapy in First-line H. Pylori Eradication
Lead Sponsor:
National Cheng-Kung University Hospital
Conditions:
Helicobacter Pylori Infection
Dysbiosis
Eligibility:
All Genders
18-100 years
Phase:
PHASE4
Brief Summary
Helicobacter pylori (H. pylori) infection is the major cause of gastritis, peptic ulcer disease, and gastric cancer in adults. Bismuth-based quadruple therapy is recommended by a recent review to be t...
Detailed Description
Bismuth-based quadruple therapy is recommended by a recent review to be the first-line treatment for H. pylori eradication, replacing clarithromycin-based triple therapy. It is because the eradication...
Eligibility Criteria
Inclusion
- Patients who are \> 18 years
- Receive gastroscopy because of dyspepsia, acid regurgitation, melena, hematemesis, or others
Exclusion
- Bleeding diathesis,
- Major organic diseases
- Malignancy
- Diseases treated with chemotherapy within one month
- Diseases treated with steroids within one month
- Diseases treated with antibiotics within one month,
- Users of aspirin within four weeks before enrollment
- Users of nonsteroidal anti-inflammatory drugs within four weeks before enrollment
- Users of cyclooxygenase-2 selective inhibitors within four weeks before enrollment
- History of H. pylori eradication
- Ingest probiotics or probiotics-containing yogurt with a frequency of \>= twice per week one month prior to enrollment
Key Trial Info
Start Date :
May 6 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2028
Estimated Enrollment :
312 Patients enrolled
Trial Details
Trial ID
NCT04527055
Start Date
May 6 2020
End Date
July 31 2028
Last Update
June 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Helicobacter pylori study group, National Cheng Kung University Hospital
Tainan, Taiwan, 704302